CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 33 enrolled
Drug / intervention
Adderall-XR +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02803229
NCT02803229Phase 3Completed
CompareCT.gov

Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder

New York State Psychiatric Institute·interventional·Posted Jun 16, 2016·Updated Apr 9, 2021

In Brief

A Phase 3 clinical trial evaluating Adderall-XR and Matched placebo for Cannabis Use Disorder and Attention-deficit/Hyperactivity Disorder. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The proposed protocol is a double-blind, placebo-controlled outpatient study of the safety and benefit of Extended-release mixed amphetamine salt (Adderall-XR, MAS-XR) in the treatment of individuals with Cannabis Use Disorder (CUD) and Attention-deficit/Hyperactivity Disorder (ADHD). The investigators plan to enroll 50 and randomize 40 of these patients in the trial. The primary objective of the study is to determine the efficacy of MAS-XR in promoting cannabis abstinence among individuals with CUD and in promoting a decrease of ADHD symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Use Disorder, Attention-deficit/Hyperactivity Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 16, 2016
Enrollment StartJul 1, 2016
Primary CompletionJun 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.0 years ago

Interventions

Adderall-XRdrug

Matched placebodrug

matched placebo provided for placebo arm